TAB 7

1

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
AT CHARLESTON

_____X

THE CITY OF HUNTINGTON, : Civil Action

Plaintiff, : No. 3:17-cv-01362

V.

AMERISOURCEBERGEN DRUG CORPORATION, et al.,

Defendants. :

CABELL COUNTY COMMISSION, : Civil Action

Plaintiff, : No. 3:17-cv-01665

v. :

AMERISOURCEBERGEN DRUG : CORPORATION, et al., :

Defendants. : x

BENCH TRIAL - VOLUME 10

BEFORE THE HONORABLE DAVID A. FABER, SENIOR STATUS JUDGE
UNITED STATES DISTRICT COURT
IN CHARLESTON, WEST VIRGINIA

MAY 14, 2021

but in light of the fact that we are putting our witness -their witness -- I'm sorry -- our witness in their case, we
simply don't know the scope and extent to which current
information would be discussed.

So, we have discussed this proposal with the plaintiffs and my understanding is that they do not agree that we could make specific requests for the documents not to be broadcast to the overflow room or request sealing of specific portions of testimony or specific documents subsequent to today's testimony.

THE COURT: Do we have the ability to do this? We do?

Okay. Mr. Farrell?

MR. FARRELL: Thank you, Judge. On behalf of the plaintiffs, we object to -- this is open court and we object to the sealing of any document or any testimony in a public nuisance case brought on behalf of the public to abate this epidemic. That's point number one.

Point number two, we don't know what documents they're referencing because the Court has not required the defendants to disclose what documents they're going to use with these witnesses.

Number three, discovery in this case was blocked -- not blocked. That's the wrong word. There's a temporal scope to discovery in this case. On the back end, it was 2006 and

I believe on the front end, it was as of time of remand sometime in 2019. So, for purposes of discovery disclosures, we have not conducted any discovery nor been permitted to conduct any discovery on the current scope of their program.

And, finally, on the relevance standpoint, eliciting testimony about current customers or current OMP programs, we fail to see how it has anything to do with the flood of pills that were sold into West Virginia, into this community, giving rise to the opioid epidemic.

MS. MCCLURE: May I respond? Your Honor, certain of the documents that I'm thinking of today would be documents that have been produced to plaintiffs that are in the record covered by the discovery period, which ends, I honestly don't recall, sometime 2018 or 2019.

That said, some of the information within those documents, despite the fact that it may be from 2018, would still today be considered confidential by the company. And, to be clear, this is confidential because the purpose of the Diversion Control Program is, in fact, to protect the public.

The second point that Mr. Farrell was making regarding relevance, the plaintiffs have articulated in this case that they are seeking an abatement-only forward-looking remedy.

So, Mr. May's testimony today, Mr. Farrell is free to

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

stand up and object to the extent that he believes that the testimony is information that he was -- I believe he used the word prevented from obtaining in the course of discovery, but Mr. May is the present -- the present -- the Vice President of Diversion Control. The plaintiffs are seeking a forward-only abatement remedy and the current state of the program, regardless of whether the plaintiffs are choosing to focus in their examination on far distant past and the fact that, what they call the number of pills that were submitted long ago, the fact that they're choosing to focus on that does not prevent us from pointing out to Your Honor what is our Diversion Control Program today. They're calling this witness, Mr. May. He currently operates the Diversion Control Program. We're entitled to mount a defense to that. But, to be clear, the documents that I'm talking about showing or potentially broadcasting and would have confidentiality concerns are documents that the plaintiffs have. THE COURT: Let me make sure I understand you. You're saying this is confidential customer information that shouldn't be disclosed? MS. MCCLURE: So it's not necessarily information of the customer. It is in the sense that we have -- let me give you an example -- parameters that are set for each

Ayme A. Cochran, RMR, CRR (304) 347-3128